Parameter
| Biomarker | hs-cTn / cTn | Full name | High-sensitivity cardiac troponin / Cardiac troponin | Molecular Type | Proteins |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | cTnI: ~24 kDa; cTnT: ~37 kDa | Core Functional Dimensions | Prognostic stratification and myocardial injury assessment | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Myocardium | Test Sample / Technology Platform | Plasma (high-sensitivity immunoassay, chemiluminescence) | ||
| Pathobiological Mechanisms | Myocardial stress/ischemia/necrosis in HF results in the release of intracellular cTn, which reflects the degree of myocardial microdamage and is independent of the pathological process of ventricular stress | ||||
| Clinical Availability Status | Clinical available/guidelines recommend: - ESC guidelines (2021) recommended for the prognosis of patients with HF assessment (Ⅱ class a recommendation); Elevated hs-cTn (>99th percentile) in acute HF suggests a 2-to 3-fold increase in 1-year mortality | ||||
| Notes and Dynamics | Mild elevated hs-cTn was still associated with poor outcomes in patients with chronic HF, with AUC values of 0.72-0.78; Hs-cTn combined with NT-proBNP could improve the accuracy of risk stratification in HFpEF patients (NRI=0.18). The level of hs-cTn in patients with ischemic HF is significantly higher than that in patients with non-ischemic HF, which can help to identify the cause of HF | ||||